Stocktoria

Lantheus Holdings, Inc. LNTH

Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2015-06-25 · LEI

Lantheus Holdings, Inc. financials (annual)

Revenue
$301.9M $331.4M $343.4M $347.3M $339.4M $425.2M $935.1M $1.30B $1.53B $1.54B 2016201720182019202020212022202320242025
Net income
$123.4M $40.5M $31.7M -$13.5M -$71.3M $28.1M $326.7M $312.4M $233.6M 2016201720182019202020212022202320242025
Free cash flow
2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$1.5B$1.5B$1.3B$935.1M$425.2M$339.4M$347.3M$343.4M$331.4M$301.9M
Gross profit$942.0M$988.3M$709.5M$581.7M$187.7M$138.8M$174.8M$174.9M$162.1M$137.8M
R&D expense$177.3M$168.1M$77.7M$311.7M$45.0M$32.8M$20.0M$17.1M$18.1M$12.2M
Operating income$310.8M$457.0M$364.6M$36.2M-$60.8M-$4.2M$51.7M$64.5M$51.9M$56.6M
Interest expense$20.0M$7.2M$7.8M$9.5M$13.6M$17.4M$18.4M$26.6M
Income tax$80.2M$118.5M$84.3M-$1.3M-$3.8M$2.0M-$3.0M$9.0M-$83.7M$1.5M
Net income$233.6M$312.4M$326.7M$28.1M-$71.3M-$13.5M$31.7M$40.5M$123.4M
EPS (diluted)$3.41$4.36$4.65$0.40$-1.06$-0.25$0.79$1.03$3.17$0.82
Operating cash flow$390.1M$544.8M$305.3M$281.8M$53.9M$16.4M$80.4M$61.2M$54.8M$49.6M
Cash & equivalents$359.1M$912.8M$713.7M$415.7M$98.5M$79.6M$92.9M$113.4M$76.3M$51.2M
Inventory$64.7M$68.0M$64.0M$35.5M$35.1M$35.7M$29.2M$33.0M$26.1M$17.6M
Total assets$2.2B$2.0B$1.7B$1.3B$863.8M$869.8M$405.9M$439.8M$383.9M$255.9M
Total liabilities$1.1B$892.3M$835.3M$874.1M$399.3M$355.6M$291.3M$368.8M$360.6M$362.4M
Shareholders' equity$1.1B$1.1B$815.9M$447.1M$464.4M$514.2M$114.6M$71.0M$23.3M-$106.5M

Growth · year-over-year · Revenue CAGR 19.9%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+0.5%+18.3%+38.6%+119.9%+25.3%-2.3%+1.2%+3.6%+9.8%+2.9%
Net income growth-25.2%-4.4%+1063.9%-142.5%-21.8%-67.2%
EPS growth-21.8%-6.2%+1062.5%-131.6%-23.3%-67.5%+286.6%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.